WO2013161928A1 - Dérivé oxazolotriazole et composition médicamenteuse contenant celui-ci - Google Patents

Dérivé oxazolotriazole et composition médicamenteuse contenant celui-ci Download PDF

Info

Publication number
WO2013161928A1
WO2013161928A1 PCT/JP2013/062181 JP2013062181W WO2013161928A1 WO 2013161928 A1 WO2013161928 A1 WO 2013161928A1 JP 2013062181 W JP2013062181 W JP 2013062181W WO 2013161928 A1 WO2013161928 A1 WO 2013161928A1
Authority
WO
WIPO (PCT)
Prior art keywords
substituted
unsubstituted
aromatic
aromatic heterocyclic
aromatic carbocyclic
Prior art date
Application number
PCT/JP2013/062181
Other languages
English (en)
Japanese (ja)
Inventor
一成 服部
健二 高谷
一穂 川瀬
夏枝 青木
義人 石田
Original Assignee
塩野義製薬株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 塩野義製薬株式会社 filed Critical 塩野義製薬株式会社
Publication of WO2013161928A1 publication Critical patent/WO2013161928A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds

Abstract

L'invention concerne un composé de formule (I) ou un sel pharmaceutiquement acceptable de celui-ci. Dans ladite formule, R1a est un atome d'hydrogène ou analogue; R7 est le groupe représenté par -C(R3a)(R4a)-N(R5a)-Y­ a-R6a ou analogue; R3a et R4a sont tous deux des atomes d'hydrogène ou forment ensemble un oxo ou analogue; R5a est un atome d'hydrogène ou analogue; -Ya- est une liaison simple ou analogue; R6a est un atome d'hydrogène ou analogue; R8 est le groupe représenté par -C(R16)(R17)-N(R18)-X-R19 ou analogue; R16 et R17 sont tous deux des atomes d'hydrogène ou forment ensemble un oxo ou analogue; R18 est un atome d'hydrogène ou analogue; -X- représente une liaison simple ou analogue; et R19 est un atome d'hydrogène ou analogue).
PCT/JP2013/062181 2012-04-26 2013-04-25 Dérivé oxazolotriazole et composition médicamenteuse contenant celui-ci WO2013161928A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012-100687 2012-04-26
JP2012100687 2012-04-26

Publications (1)

Publication Number Publication Date
WO2013161928A1 true WO2013161928A1 (fr) 2013-10-31

Family

ID=49483232

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2013/062181 WO2013161928A1 (fr) 2012-04-26 2013-04-25 Dérivé oxazolotriazole et composition médicamenteuse contenant celui-ci

Country Status (1)

Country Link
WO (1) WO2013161928A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020054657A1 (fr) 2018-09-10 2020-03-19 科研製薬株式会社 Dérivé d'amide hétéroaromatique et médicament le contenant

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0243540A (ja) * 1988-08-03 1990-02-14 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料
WO1996031517A1 (fr) * 1995-04-04 1996-10-10 E.I. Du Pont De Nemours And Company Anilides herbicides heteroaryl-substitues
WO2010079443A1 (fr) * 2009-01-12 2010-07-15 Pfizer Limited Dérivés sulfonamides
US20120010182A1 (en) * 2010-07-09 2012-01-12 Icagen Inc. Chemical Compounds

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0243540A (ja) * 1988-08-03 1990-02-14 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料
WO1996031517A1 (fr) * 1995-04-04 1996-10-10 E.I. Du Pont De Nemours And Company Anilides herbicides heteroaryl-substitues
WO2010079443A1 (fr) * 2009-01-12 2010-07-15 Pfizer Limited Dérivés sulfonamides
US20120010182A1 (en) * 2010-07-09 2012-01-12 Icagen Inc. Chemical Compounds

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BALL,C. ET AL.: "[1,3]Oxazolo[3,2-b][1,2,4] triazoles.", A VERSATILE SYNTHESIS OF A NOVEL HETEROCYCLE, TETRAHEDRON LETTERS, vol. 51, no. 30, 26 May 2010 (2010-05-26), pages 3907 - 3909 *
PILLA,M. ET AL.: "The identification of novel orally active mGluR5 antagonist GSK2210875", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 20, no. 24, 2 November 2010 (2010-11-02), pages 7521 - 7524 *
SULTAN CHOWDHURY ET AL.: "Discovery of XEN907, a spirooxindole blocker of Navl.7 for the treatment of pain", BIOORG. MED. CHEM. LETT., vol. 21, no. 12, 24 April 2011 (2011-04-24), pages 3676 - 3681 *
T. SAMBAIAH ET AL.: "Synthesis of 2-Aryl[1,2,4] triazolo[5,1-b]benzoxazoles by Oxidative Cyclization of N-(Benzoxazol-2-yl)benzamidines", SYNTHESIS, May 1990 (1990-05-01), pages 422 - 424 *
TOZKOPARAN,B. ET AL.: "Design and synthesis of some thiazolotriazolyl esters as anti- inflammatory and analgesic agents", MEDICINAL CHEMISTRY RESEARCH, vol. 21, no. 2, 12 December 2010 (2010-12-12), pages 192 - 201 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020054657A1 (fr) 2018-09-10 2020-03-19 科研製薬株式会社 Dérivé d'amide hétéroaromatique et médicament le contenant
KR20210057008A (ko) 2018-09-10 2021-05-20 가껭세이야꾸가부시기가이샤 신규한 헤테로방향족 아미드 유도체 및 이를 함유하는 약제

Similar Documents

Publication Publication Date Title
KR101867110B1 (ko) 트라이아진 유도체 및 그것을 함유하는 진통 작용을 갖는 의약 조성물
JP6281952B2 (ja) Ｈｉｖ複製阻害剤
JP2016501827A (ja) Ｂａｃｅ１阻害作用を有するジヒドロオキサジンまたはオキサゼピン誘導体
WO2013062028A1 (fr) Inhibiteur de la réplication du vih
WO2013002357A1 (fr) Inhibiteur de réplication du vih
JP6099051B2 (ja) Ｐｇｄ２受容体アンタゴニスト活性を有するへテロ環誘導体
JP6725177B2 (ja) ９員縮合環誘導体
WO2016084922A1 (fr) Dérivé 1,2,4-triazine et composition pharmaceutique correspondante
WO2013157622A1 (fr) Inhibiteur de la réplication du vih
WO2016088838A1 (fr) Dérivé de purine et composition pharmaceutique le contenant
JP6579549B2 (ja) Ｈｉｖ複製阻害作用を有する３環性複素環誘導体
JPWO2015056782A1 (ja) 新規アルキレン誘導体
WO2013035827A1 (fr) Nouveau dérivé d'oléfine
JPWO2013146754A1 (ja) Ｔｒｐｖ４阻害活性を有する芳香族複素５員環誘導体
JP2014101354A (ja) Ｂａｃｅ１阻害作用を有するオキサジン誘導体
WO2018079759A1 (fr) Hétérocycle fusionné ayant une activité inhibitrice de trka et dérivé carbocycle fusionné
WO2015147247A1 (fr) Dérivé tricyclique présentant une activité inhibitrice de la réplication du vih
WO2014175370A1 (fr) Dérivé de pyrrolidine et composition pharmaceutique en contenant
WO2017204316A1 (fr) Dérivé de 5-oxo-1,2,4-triazine et composition pharmaceutique correspondante
WO2015199206A1 (fr) Dérivé de cycle à six chaînons ayant une activité inhibitrice de trpv4
WO2017204318A1 (fr) Dérivé de 1,2,4-triazine
WO2018074565A1 (fr) Dérivé hétérocyclique à 6 chaînons contenant de l'azote et composition pharmaceutique le contenant
JP2014080395A (ja) アミノラクタム誘導体およびそれらを含有する医薬組成物
JP2017071603A (ja) ジヒドロチアジンまたはジヒドロオキサジン誘導体を含有する医薬組成物
WO2016098793A1 (fr) Dérivé thiazole ayant un groupe guanidyle cyclique

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13781652

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13781652

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP